Allarity Therapeutics

Yahoo Finance • 16 days ago

Allarity Therapeutics registers 1.56M shares for resale

* Allarity Therapeutics (NASDAQ:ALLR [https://seekingalpha.com/symbol/ALLR]) prospectus covers up to 1.56M shares of common stock offered by a selling stockholder. * Shares consist of: 760,916 common shares, and 801,584 shares issuabl... Full story

Yahoo Finance • 19 days ago

Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months

- Kaplan-Meier analyses show for the first time that median Overall Survival exceeds 25 months for Platinum Resistant  and Refractory Ovarian Cancer Patients receiving stenoparib/2X-121 twice daily - Two patients continue on therapy now... Full story

Yahoo Finance • 24 days ago

Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025

TARPON SPRINGS, Fla., September 17, 2025 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pat... Full story

Yahoo Finance • last month

These stocks have an unusual volume in today's session

Unusual volume stocks are being observed in Wednesday's session. [unusualvolume] TOP UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT INHD [https://www.chartmill.com/stock/quote/INHD/profile] 31.57% INNO HOLDINGS INC (NASDAQ:I... Full story

Yahoo Finance • 2 months ago

Top stock movements in today's session.

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. [topmovers] GAINERS TICKER CHANGE COMMENT IVVD [https://www.chartmill.com/stock/quote/IVVD/profile] 90.28% INVIVYD INC'S... Full story

Yahoo Finance • 2 months ago

Check out the stocks that are attracting the most attention and driving market activity.

Let's dive into the action on the US markets on Tuesday. Here are the most active stocks that are driving the market today. [mostactive] TOP MOST ACTIVE STOCKS TICKER CHANGE COMMENT IXHL [https://www.chartmill.com/stock/quote... Full story

Yahoo Finance • 2 months ago

Tuesday's session: top gainers and losers

Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis. [topmovers] TOP GAINERS TICKER CHANGE COMMENT NUKKW [https://www.ch... Full story

Yahoo Finance • 2 months ago

BC-Most Active Stocks

NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change Allarity Therapeutics Inc. 196,807,150 2.28 1.75 1.84 +0.8987 Incannex H... Full story

Yahoo Finance • 2 months ago

Traders are paying attention to the gapping stocks in Tuesday's session.

In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down. [gap] TODAY'S GAP UP STOCKS TICKER CHANGE COMMENT HKPD [https://www.chartmill.com/s... Full story

Yahoo Finance • 2 months ago

Tuesday's pre-market session: top gainers and losers

Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics. [premarket] GAINERS TICKER CHANGE COMMENT IVVD [https://www.chartmill.com/stock/quote/IVVD/profile] 132.0% Investors witness... Full story

Yahoo Finance • 2 months ago

FDA grants fast track designation for Allarity's ovarian cancer drug

TARPON SPRINGS, Fla. - Allarity Therapeutics, Inc. (NASDAQ:ALLR), a small-cap biotech company with a market capitalization of $14.45 million, announced Tuesday that the U.S. Food and Drug Administration has granted Fast Track designation t... Full story

Yahoo Finance • 2 months ago

Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer

Allarity Therapeutics, Inc. TARPON SPRINGS, Fla., August 26, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differenti... Full story

Yahoo Finance • 2 months ago

Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships

- Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial - Expanded global IP protection by securing Australian patent acceptance for the stenoparib DRP® companion diagnostic - Secured new service contract with EU b... Full story

Yahoo Finance • 3 months ago

Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization

TARPON SPRINGS, Fla., July 15, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway... Full story

Yahoo Finance • 3 months ago

Allarity Therapeutics appoints Jeff Ervin as CFO

* Allarity Therapeutics (NASDAQ:ALLR [https://seekingalpha.com/symbol/ALLR]) announced on Monday the appointment of Jeff Ervin as the company’s new chief financial officer (CFO).  * Ervin succeeds Alexander Epshinsky, who will remain e... Full story

Yahoo Finance • 3 months ago

Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer

TARPON SPRINGS, Fla., July 7, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway... Full story

Yahoo Finance • 3 months ago

Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic

TARPON SPRINGS, Fla., June 30, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway... Full story

Yahoo Finance • 3 months ago

Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer

TARPON SPRINGS, Fla., June 27, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway... Full story

Yahoo Finance • 4 months ago

Allarity Therapeutics Announces Changes to Board of Directors

TARPON SPRINGS, Fla., June 11, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway... Full story

Yahoo Finance • 4 months ago

Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer

TARPON SPRINGS, Fla., June 2, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway... Full story